These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 20373147)

  • 1. Adoptive T-cell immunotherapy of cancer using chimeric antigen receptor-grafted T cells.
    Davies DM; Maher J
    Arch Immunol Ther Exp (Warsz); 2010 Jun; 58(3):165-78. PubMed ID: 20373147
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chimeric T cells for adoptive immunotherapy of cancer: using what have we learned to plan for the future.
    Peinert S; Kershaw MH; Prince HM
    Immunotherapy; 2009 Nov; 1(6):905-12. PubMed ID: 20635906
    [No Abstract]   [Full Text] [Related]  

  • 3. Spotlight on chimeric antigen receptor engineered T cell research and clinical trials in China.
    Luo C; Wei J; Han W
    Sci China Life Sci; 2016 Apr; 59(4):349-59. PubMed ID: 27009301
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hurdles of CAR-T cell-based cancer immunotherapy directed against solid tumors.
    Zhang BL; Qin DY; Mo ZM; Li Y; Wei W; Wang YS; Wang W; Wei YQ
    Sci China Life Sci; 2016 Apr; 59(4):340-8. PubMed ID: 26965525
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Strategies to improve the clinical performance of chimeric antigen receptor-modified T cells for cancer.
    Zhang Q; Li H; Yang J; Li L; Zhang B; Li J; Zheng J
    Curr Gene Ther; 2013 Feb; 13(1):65-70. PubMed ID: 23256743
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CARs in the Lead Against Multiple Myeloma.
    Ormhøj M; Bedoya F; Frigault MJ; Maus MV
    Curr Hematol Malig Rep; 2017 Apr; 12(2):119-125. PubMed ID: 28233151
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetically redirected T lymphocytes for adoptive immunotherapy of solid tumors.
    Leuci V; Mesiano G; Gammaitoni L; Aglietta M; Sangiolo D
    Curr Gene Ther; 2014 Feb; 14(1):52-62. PubMed ID: 24365144
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CAR T cells targeting solid tumors: carcinoembryonic antigen (CEA) proves to be a safe target.
    Holzinger A; Abken H
    Cancer Immunol Immunother; 2017 Nov; 66(11):1505-1507. PubMed ID: 28755091
    [No Abstract]   [Full Text] [Related]  

  • 9. Armed T cells with CAR for cancer immunotherapy.
    Wei YQ
    Sci China Life Sci; 2016 Apr; 59(4):331-2. PubMed ID: 27080712
    [No Abstract]   [Full Text] [Related]  

  • 10. Treatment of solid tumors with chimeric antigen receptor-engineered T cells: current status and future prospects.
    Di S; Li Z
    Sci China Life Sci; 2016 Apr; 59(4):360-9. PubMed ID: 26968709
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chimeric antigen receptors for T cell immunotherapy: current understanding and future directions.
    Curran KJ; Pegram HJ; Brentjens RJ
    J Gene Med; 2012 Jun; 14(6):405-15. PubMed ID: 22262649
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adoptive therapy with CAR redirected T cells for hematological malignancies.
    Li S; Yang Z; Shen J; Shan J; Qian C
    Sci China Life Sci; 2016 Apr; 59(4):370-8. PubMed ID: 27009302
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Establishing guidelines for CAR-T cells: challenges and considerations.
    Wang W; Qin DY; Zhang BL; Wei W; Wang YS; Wei YQ
    Sci China Life Sci; 2016 Apr; 59(4):333-9. PubMed ID: 26965523
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chimeric Antigen Receptor T Cell Based Immunotherapy for Cancer.
    Li F; Zhang T; Cao L; Zhang Y
    Curr Stem Cell Res Ther; 2018; 13(5):327-335. PubMed ID: 29676233
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current status and regulatory perspective of chimeric antigen receptor-modified T cell therapeutics.
    Kim MG; Kim D; Suh SK; Park Z; Choi MJ; Oh YK
    Arch Pharm Res; 2016 Apr; 39(4):437-452. PubMed ID: 26895243
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Strategies to genetically engineer T cells for cancer immunotherapy.
    Spear TT; Nagato K; Nishimura MI
    Cancer Immunol Immunother; 2016 Jun; 65(6):631-49. PubMed ID: 27138532
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chimeric antigen receptor-redirected T cells return to the bench.
    Geldres C; Savoldo B; Dotti G
    Semin Immunol; 2016 Feb; 28(1):3-9. PubMed ID: 26797495
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Perspectives on Chimeric Antigen Receptor T-Cell Immunotherapy for Solid Tumors.
    Kosti P; Maher J; Arnold JN
    Front Immunol; 2018; 9():1104. PubMed ID: 29872437
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor Antigen and Receptor Densities Regulate Efficacy of a Chimeric Antigen Receptor Targeting Anaplastic Lymphoma Kinase.
    Walker AJ; Majzner RG; Zhang L; Wanhainen K; Long AH; Nguyen SM; Lopomo P; Vigny M; Fry TJ; Orentas RJ; Mackall CL
    Mol Ther; 2017 Sep; 25(9):2189-2201. PubMed ID: 28676342
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Viral Engineering of Chimeric Antigen Receptor Expression on Murine and Human T Lymphocytes.
    Hammill JA; Afsahi A; Bramson JL; Helsen CW
    Methods Mol Biol; 2016; 1458():137-57. PubMed ID: 27581020
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.